After 8 weeks, the treatment group showed a 20% increase in hydration levels, measured by corneometry, and improved epidermal and dermal thickness due to enhanced glycosaminoglycan synthesis (Krger et al., 2010)
13 , eabe1202 (2020)
RiskBenefit Assessment and Pharmacovigilance Needs Given the widespread use of GLP-1RAs and other incretin-based agents for obesity and T2D, comprehensive evaluation of even common GI adverse effects remains limited
Meet the experts Related content and resources As consumers adopt GLP-1 medications and shift toward smaller, nutrient-dense meals, the demand for high-protein, fibre-rich and clean-label products with less sugar is accelerating

Gastrointestinal adverse events Very common (10% or more): Diarrhea (35%), abdominal pain (21%), vomiting (21%), nausea (12%) Common (1% to 10%): Constipation, dyspepsia, gastrointestinal disorder, melena Very rare (less than 0.01%): Abdominal cramps [Ref] Nervous system Very common (10% or more): Headache (37%), dizziness (18%), paresthesia (12%) Common (1% to 10%): Hypertonia, vertigo, taste perversion Frequency not reported : Seizures (with or without pre-existing seizure activity), increase in seizure frequency and/or severity [Ref] Metabolic Very common (10% or more): Hypercalcemia (15%), hypervolemia (12%) Common (1% to 10%): Anorexia, hyperkalemia [Ref] There are reports from clinical trials of significant hypertriglyceridemia associated with high doses of levocarnitine (3 g/day) given to uremic dialysis patients
US-licensed pharmacist on every lot Pharmacist holds release authority No batch ships unsigned ever 05 Dispatch Ships from Dallas in 48 hours